Company intelligence / Profile preview

Intercell Biomedical

Vienna, Vienna, Austria

Ownership: Private
Employees: ~400
Development stage: Other

Overview

Intercell was a biotechnology company specializing in the development of innovative vaccines for the prevention and treatment of infectious diseases. The company successfully developed and commercialized IXIARO, a vaccine against Japanese encephalitis, which received approval from the FDA and EMA. Intercell's technology focused on its proprietary Antigen Identification Program (AIP) and the IC31 adjuvant platform. In 2013, Intercell merged with the French biotech company Vivalis to form Valneva SE, creating a leading European player in the vaccine industry.

Therapeutic areas: Infectious Diseases
Modalities: VaccineMonoclonal antibodyAdjuvant
Industry: Biotech

Partnerships

NovartisMerck & Co.GlaxoSmithKlineSanofi Pasteur

Beyond the preview

Go deeper on Intercell Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intercell Biomedical.

Explore the full profile